Patients' Real-World Experiences With Pharmacologic Therapies for Irritable Bowel Syndrome With Constipation: A Mixed-Methods Analysis and Classification of Social Media and E-Forum Posts: GI Signals

Motility prospective cohort · n=7,328 · Sep 1, 2026 · Neurogastro Motil · IF 3.5

Patients' Real-World Experiences With Pharmacologic Therapies for Irritable Bowel Syndrome With Constipation: A Mixed-Methods Analysis and Classification of Social Media and E-Forum Posts.

Epidemiologyartificial intelligencehealth servicesIBS

Clinical takeawayWhen prescribing FDA-approved therapies for IBS-C (e.g., linaclotide, lubiprostone), proactively discuss the potential for variable efficacy, common side effects like diarrhea and nausea, and the social anxiety they can cause. Explicitly ask about barriers like cost and insurance coverage to improve adherence.

What it foundAnalysis of over 7,300 social media and e-forum posts from IBS-C patients using FDA-approved therapies identified four key themes driving patient experience and adherence: variable efficacy, treatment burden (including side effects like diarrhea and nausea, and social anxiety), intentional non-adherence, and access barriers like cost and insurance coverage.

ContextThis study uses social media and e-forum analysis to confirm and structure common clinical observations that real-world patient experience with IBS-C medications often diverges from clinical trial data due to side effects, cost, and variable efficacy, reinforcing the need for shared decision-making.

Refinessuggested applicable standard· American College of Gastroenterology, 'ACG Clinical Guideline: Management of Irritable Bowel Syndrome', 2021

Decision at stakethe recommendation to use chloride channel activators and guanylate cyclase activators for IBS-C

… IBS-C: chloride channel activators (strong, moderate) and guanylate cyclase activators (strong, high); AGAINST PEG products for global IBS-C symptoms (conditional, low); tegaserod reserved for women younger than 65 with ≤1 cardiovascular risk factor who have not adequately responded to secretagogues (strong/conditional, low). …

From our summary of this standard, unedited — the part the paper bears on. … marks omitted text. Our wording, not the guideline's; read the source for its own text. The rest of this standard includes IBS-D.

Our full summary of this standard

Diagnosis: use a positive diagnostic strategy based on Rome IV criteria rather than a strategy of exclusion (strong for cost-effectiveness, high quality; consensus for time-to-therapy), and categorize by IBS subtype (consensus). In patients with IBS and diarrhea symptoms: check celiac serology (strong, moderate) and, in those WITHOUT alarm features, fecal calprotectin (or fecal lactoferrin) plus CRP to rule out IBD (strong; moderate quality for CRP/calprotectin, very low for lactoferrin). Recommend AGAINST routine stool testing for enteric pathogens (conditional, low) and AGAINST routine colonoscopy in patients younger than 45 without warning signs (conditional, low). Anorectal physiology testing only when symptoms suggest a pelvic floor disorder and/or for refractory constipation not responding to standard medical therapy (consensus). Treatment, all subtypes: soluble, not insoluble, fiber (strong, moderate); a LIMITED trial of a low-FODMAP diet (conditional, very low); gut-directed psychotherapies for global symptoms (conditional, very low); TCAs for global symptoms (strong, moderate); peppermint suggested (conditional, low); antispasmodics for abdominal pain (conditional, low); AGAINST probiotics (conditional, very low), AGAINST fecal transplant (strong, very low). IBS-C: chloride channel activators (strong, moderate) and guanylate cyclase activators (strong, high); AGAINST PEG products for global IBS-C symptoms (conditional, low); tegaserod reserved for women younger than 65 with ≤1 cardiovascular risk factor who have not adequately responded to secretagogues (strong/conditional, low). IBS-D: rifaximin (strong, moderate); alosetron only for women with severe IBS-D who have failed conventional therapy (conditional, low); mixed opioid agonists/antagonists, i.e. eluxadoline (conditional, moderate); AGAINST bile acid sequestrants (conditional, very low).

American College of Gastroenterology, 'ACG Clinical Guideline: Management of Irritable Bowel Syndrome', 2021 · reviewed 2026-07-21 ↗

Khalil C … Almario CV · Neurogastroenterology and Motility · IF 3.5 · PubMed ↗Permalink